Nuvectis' NXP200 Shows Complete Responses In BRAF-Mutated Recurrent Gliomas
Nuvectis Pharma (NVCT) reported positive Phase 1b data for NXP200, a BRAF inhibitor, in recurrent gliomas at ESMO 2026. The study showed 40% ORR in high-grade and 42.9% in low-grade gliomas, with manageable safety profile. NVCT plans to submit a U.S. IND application by year-end. Shares are down 8.08% at $18.43.
How this was made
The 30-second read
Why it matters
The disclosed ORR and deep response rates are substantially higher than historical benchmarks for BRAF‑mutated gliomas, suggesting a differentiated product.
Market read
First‑time disclosure of promising Phase 1b results could trigger a short‑term rally in NVCT and influence peer biotech valuations.
What to watch
The trial size is small (27 patients) and long‑term safety/overall survival data are pending.
Background
Nuvectis Pharma (NVCT) is a clinical‑stage biotech developing brain‑penetrant BRAF inhibitors. The data were presented at the 2026 ESMO Congress.
Ticker impact
Nuvectis Pharma reported positive Phase 1b data for its BRAF inhibitor NXP200 in glioma patients.
upward pressure as the market prices in the encouraging efficacy and safety results
Phase 1b data with 40% ORR and deep responses is material for a biotech; no prior public disclosure of these results.
Market effects
May boost sentiment for other BRAF‑targeted or glioma‑focused biotech firms.
Limited to US‑listed biotech investors.
Modest; primarily relevant to specialty oncology investors.
Counterpoint
Some investors may wait for later‑stage data before committing, citing high attrition rates in oncology trials.
Key entities
- companyNuvectis Pharma, Inc.
US‑listed biotech developing NXP200.
- companyHaisco Pharmaceutical Group
Licensor of NXP200 outside Greater China.
